{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:52:43Z","timestamp":1792806763394,"version":"4.5.0"},"reference-count":112,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Conventional diabetes therapy primarily targets HbA1c using a standardized, stepwise approach, often neglecting individual clinical and diagnostic phenotypes. In this second part of our discussion, we present an alternative strategy. After phenotyping the patient, we initiate a targeted pharmacological combination therapy tailored to the individual\u2019s underlying pathophysiology, alongside lifestyle modifications. Sulfonylureas are completely avoided in this approach. Instead, medications are selected based on their alignment with the patient\u2019s phenotype and absence of contraindications. Early insulin therapy, for example, is particularly effective in patients with \u03b2-cell-dysfunction-driven diabetes, whereas GLP-1-supported weight reduction and glitazone therapy are more suitable for insulin-resistance-driven diabetes. For monitoring and determining when temporary therapy intensification may be necessary, we rely on a combination of functional biomarkers (intact proinsulin, adiponectin, hsCRP, and leptin) and conventional clinical parameters (HbA1c, BMI, lipids, blood pressure). Using this personalized strategy, we have consistently achieved long-term glycemic control\u2014often maintaining normal HbA1c levels for up to 15 years in our patients so far.<\/jats:p>","DOI":"10.3390\/jpm16040229","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:22:47Z","timestamp":1776691367000},"page":"229","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Personalized Diabetes Therapy Part 2\u2014Individual Diabetes Treatment (Standard of Care Plus, SOC+)"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7103-6973","authenticated-orcid":false,"given":"Julia","family":"Jantz","sequence":"first","affiliation":[{"name":"Pf\u00fctzner Science & Health Institute, D-55128 Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2385-0887","authenticated-orcid":false,"given":"Andreas","family":"Pf\u00fctzner","sequence":"additional","affiliation":[{"name":"Pf\u00fctzner Science & Health Institute, D-55128 Mainz, Germany"},{"name":"Institute for Digital Technologies in Medicine & Dentistry, Institut Sup\u00e9rieur der Formation Continue, L-5393 Schuttrange, Luxembourg"},{"name":"Department of Biotechnology & Bioinformatics, Technical University Bingen, D-55411 Bingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"ref_1","unstructured":"American Diabetes Association Professional Practice Committee (2024). 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2024. Diabetes Care, 47, S1\u2013S308."},{"key":"ref_2","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), and Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2024, March 31). Nationale VersorgungsLeitlinie Typ-2-Diabetes\u2014Teilpublikation der Langfassung, 2. Auflage. Version 1. Available online: https:\/\/www.ddg.info\/fileadmin\/user_upload\/05_Behandlung\/01_Leitlinien\/Evidenzbasierte_Leitlinien\/2021\/diabetes-2aufl-vers1.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s11428-020-00608-9","article-title":"Therapie des Typ-2-Diabetes [Treatment of type 2 diabetes]","volume":"16","author":"Landgraf","year":"2020","journal-title":"Diabetologie"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.diabet.2009.11.006","article-title":"Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes","volume":"36","author":"Ringborg","year":"2010","journal-title":"Diabetes Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12933-023-01903-7","article-title":"Impact of type 2 diabetes on life expectancy and role of kidney disease among inpatients with heart failure in Switzerland: An ambispective cohort study","volume":"22","author":"Salvador","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e44037","DOI":"10.2196\/44037","article-title":"Diabetes Life Expectancy Prediction Model Inputs and Results From Patient Surveys Compared With Electronic Health Record Abstraction: Survey Study","volume":"6","author":"Bernstein","year":"2023","journal-title":"JMIR Aging"},{"key":"ref_7","unstructured":"(2023). Emerging Risk Factors Collaboration. Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation. Lancet Diabetes Endocrinol., 11, 731\u2013742."},{"key":"ref_8","first-page":"485","article-title":"A Biomarker Concept for Assessment of Insulin resistance, \u00df-Cell Function and Chronic Systemic Inflammation in Type 2 Diabetes mellitus","volume":"54","author":"Weber","year":"2008","journal-title":"Clin. Lab."},{"key":"ref_9","first-page":"299","article-title":"\u201cGlukosekosmetik\u201d vs. Personalisierte Diabetestherapie Teil 1: Funktionelle Ph\u00e4notypisierung als Grundlage einer individuellen Typ 2 Diabetes Therapie","volume":"32","year":"2023","journal-title":"Diabetes Stoffw. Herz"},{"key":"ref_10","first-page":"11","article-title":"\u201cGlukosekosmetik\u201d vs. personalisierte Diabetestherapie Teil 2: Personalisierte Therapie","volume":"33","year":"2024","journal-title":"Diabetes Stoffw. Herz"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199602293340906","article-title":"Metformin","volume":"334","author":"Bailey","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/pgmj.47.554.777","article-title":"The hypoglycaemic action of metformin","volume":"47","author":"Frayn","year":"1971","journal-title":"Postgrad. Med. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.2337\/diabetes.49.12.2063","article-title":"Mechanism by which metformin reduces glucose production in type 2 diabetes","volume":"49","author":"Hundal","year":"2000","journal-title":"Diabetes"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34). Lancet, 352, 854\u2013865. Erratum in Lancet 1998, 352, 1558.","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1677\/JME-08-0130","article-title":"Mechanisms of metformin inhibiting lipolytic response to isoproterenol in primary rat adipocytes","volume":"42","author":"Zhang","year":"2009","journal-title":"J. Mol. Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12933-019-0900-7","article-title":"Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: A systematic review and an updated meta-analysis","volume":"18","author":"Han","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1046\/j.1463-1326.1999.00034.x","article-title":"Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes","volume":"1","author":"Hermann","year":"1999","journal-title":"Diabetes Obes. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40265-021-01665-0","article-title":"Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases","volume":"82","author":"Li","year":"2022","journal-title":"Drugs"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2337\/db10-1392","article-title":"Effects of rosiglitazone glyburide metformin on \u03b2-cell function insulin sensitivity in ADOPT","volume":"60","author":"Kahn","year":"2011","journal-title":"Diabetes"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/dom.15663","article-title":"Metformin: Therapeutic profile in the treatment of type 2 diabetes","volume":"26","author":"Bailey","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/dom.12821","article-title":"Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data","volume":"19","author":"Bain","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/1479164112465442","article-title":"Association of sulphonylurea treatment with all-cause and cardiovascular mortality: A systematic review and meta-analysis of observational studies","volume":"10","author":"Forst","year":"2013","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1503\/cmaj.050748","article-title":"Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: A population-based cohort study","volume":"174","author":"Simpson","year":"2006","journal-title":"CMAJ"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/diabetes.47.11.1663","article-title":"Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes","volume":"47","author":"Holst","year":"1998","journal-title":"Diabetes"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","article-title":"Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus","volume":"16","author":"Deacon","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Chai, S., Zhang, Y., Carr, R.D., Deacon, C.F., Zheng, C., Rajpathak, S., Chen, L., and Yu, Y. (2023). Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: A systematic review and meta-analysis. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1203187"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.regpep.2004.06.001","article-title":"Dipeptidyl peptidase IV inhibitors: How do they work as new antidiabetic agents?","volume":"128","author":"McIntosh","year":"2005","journal-title":"Regul. Pept."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ejphar.2014.08.010","article-title":"The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat","volume":"741","author":"Hansen","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1749-6632.1996.tb18621.x","article-title":"The peroxisome proliferator-activated receptors: Ligands and activators","volume":"804","author":"Forman","year":"1996","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Giglio, R.V., Papanas, N., Rizvi, A.A., Ciaccio, M., Patti, A.M., Ilias, I., Pantea Stoian, A., Sahebkar, A., Janez, A., and Rizzo, M. (2022). An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes. Medicina, 58.","DOI":"10.3390\/medicina58101475"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"s31","DOI":"10.1185\/030079902125000219","article-title":"Insulin-sensitizing agents\u2014Thiazolidinediones (glitazones)","volume":"18","author":"Barnett","year":"2002","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.2337\/db07-1828","article-title":"Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content","volume":"57","author":"Ravikumar","year":"2008","journal-title":"Diabetes"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/febs.13992","article-title":"Pioglitazone inhibits mitochondrial pyruvate metabolism and glucose production in hepatocytes","volume":"284","author":"Shannon","year":"2017","journal-title":"FEBS J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/jc.2013-2920","article-title":"Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus","volume":"98","author":"Kodama","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_36","first-page":"763","article-title":"Are thiazolidinediones a preferred drug treatment for type 2 diabetes mellitus and associated comorbidities? An update","volume":"17","author":"Hurren","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/jcem.87.6.8567","article-title":"Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients","volume":"87","author":"Miyazaki","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3132\/dvdr.2008.043","article-title":"Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk","volume":"5","author":"Forst","year":"2008","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jacc.2006.08.054","article-title":"Anti-inflammatory effects of pioglitazone and\/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: The PIOSTAT Study","volume":"49","author":"Hanefeld","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.atherosclerosis.2008.01.007","article-title":"Effects of pioglitazone and\/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study","volume":"201","author":"Leonhardt","year":"2008","journal-title":"Atherosclerosis"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Deng, M., Wen, Y., Yan, J., Fan, Y., Wang, Z., Zhang, R., Ren, L., Ba, Y., Wang, H., and Lu, Q. (2023). Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: A systematic review and Bayesian network meta-analysis of randomised controlled trials. BMC Med., 21.","DOI":"10.1186\/s12916-023-03129-6"},{"key":"ref_42","first-page":"647017","article-title":"Downregulation of the proinflammatory state of circulating mononuclear cells by short-term treatment with pioglitazone in patients with type 2 diabetes mellitus and coronary artery disease","volume":"2011","author":"Weise","year":"2011","journal-title":"PPAR Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1586\/14779072.4.4.445","article-title":"Pioglitazone: An antidiabetic drug with cardiovascular therapeutic effects","volume":"4","author":"Schneider","year":"2006","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1517\/14656566.8.12.1985","article-title":"Pioglitazone: Update on an oral antidiabetic drug with antiatherosclerotic effects","volume":"8","author":"Weber","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1472-8206.2009.00741.x","article-title":"CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone","volume":"23","author":"Betteridge","year":"2009","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1177\/193229681000400326","article-title":"High-sensitivity C-reactive protein (hs-CRP) predicts cardiovascular risk in diabetic and non-diabetic patients: Effects of insulin-sensitizing treatment with pioglitazone","volume":"4","author":"Hanefeld","year":"2010","journal-title":"J. Diabetes Sci. Technol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1161\/01.CIR.0000165072.01672.21","article-title":"Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: Results from a controlled randomized study","volume":"111","author":"Langenfeld","year":"2005","journal-title":"Circulation"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","article-title":"Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: A randomized trial","volume":"296","author":"Mazzone","year":"2006","journal-title":"JAMA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.tcm.2009.06.002","article-title":"The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus","volume":"19","author":"Polonsky","year":"2009","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1345\/aph.1K286","article-title":"Effects of thiazolidinediones on bone loss and fracture","volume":"41","author":"Murphy","year":"2007","journal-title":"Ann. Pharmacother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.4065\/78.9.1088","article-title":"Thiazolidinedione-associated congestive heart failure and pulmonary edema","volume":"78","author":"Kermani","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/S0735-1097(03)00159-1","article-title":"Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure","volume":"41","author":"Tang","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/108155890405200218","article-title":"Insulin edema in the twenty-first century: Review of the existing literature","volume":"52","author":"Chelliah","year":"2004","journal-title":"J. Investig. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00592-023-02040-z","article-title":"Insulin edema, a little known entity","volume":"60","author":"Herrero","year":"2023","journal-title":"Acta Diabetol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e202000858","DOI":"10.26508\/lsa.202000858","article-title":"Structural comparison of GLUT1 to GLUT3 reveal transport regulation mechanism in sugar porter family","volume":"4","author":"Paulsen","year":"2021","journal-title":"Life Sci. Alliance"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.psyneuen.2012.08.010","article-title":"Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression","volume":"38","author":"Kashani","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.psychres.2015.10.013","article-title":"Adjuvant pioglitazone for unremitted depression: Clinical correlates of treatment response","volume":"230","author":"Lin","year":"2015","journal-title":"Psychiatry Res."},{"key":"ref_58","first-page":"49","article-title":"PPAR-\u03b3 Agonists for the Treatment of Major Depression: A Review","volume":"50","author":"Colle","year":"2017","journal-title":"Pharmacopsychiatry"},{"key":"ref_59","first-page":"615","article-title":"Dose related acute behavioral and neurochemical profile of pioglitazone","volume":"34","author":"Ikram","year":"2021","journal-title":"Pak. J. Pharm. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.diabres.2012.05.006","article-title":"Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: A meta-analysis","volume":"98","author":"Zhu","year":"2012","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/dme.12144","article-title":"Pioglitazone and risk of bladder cancer: A meta-analysis of controlled studies","volume":"30","author":"Ferwana","year":"2013","journal-title":"Diabetes Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bcp.12145","article-title":"Pioglitazone and bladder cancer: Two studies, same database, two answers","volume":"76","author":"Zeegers","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/dme.13854","article-title":"A systematic review of observational studies of the association between pioglitazone use and bladder cancer","volume":"36","author":"Ripamonti","year":"2019","journal-title":"Diabetes Med."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Li, Y.R., Liu, C.H., Sun, W.C., Fan, P.Y., Liu, F.H., Chen, T.H., Wu, V.C., Lin, C., and Hsiao, C.C. (2021). The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone. J. Pers. Med., 11.","DOI":"10.3390\/jpm11090828"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/dme.14053","article-title":"Pioglitazone: Inexpensive; very effective at reducing HbA1c; no evidence of bladder cancer risk; plenty of evidence of cardiovascular benefit","volume":"36","author":"Ryder","year":"2019","journal-title":"Diabetes Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"G693-7","DOI":"10.1152\/ajpgi.00536.2003","article-title":"Gastrointestinal satiety signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide","volume":"286","author":"Stanley","year":"2004","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1053\/j.gastro.2007.03.048","article-title":"Gut hormones and appetite control","volume":"132","author":"Wren","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Liu, Q.K. (2024). Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1431292"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014State-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1479164118783935","article-title":"Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial","volume":"15","author":"Nauck","year":"2018","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_72","first-page":"e45421","article-title":"Safety and Efficacy of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials","volume":"15","author":"Vemulapalli","year":"2023","journal-title":"Cureus"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/DMSO.S387116","article-title":"The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials","volume":"16","author":"Aldawsari","year":"2023","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bph.15682","article-title":"Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics","volume":"179","author":"Kabahizi","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"170342","DOI":"10.1016\/j.peptides.2020.170342","article-title":"Intestinal glucagon-like peptide-1 effects on food intake: Physiological relevance and emerging mechanisms","volume":"131","author":"Krieger","year":"2020","journal-title":"Peptides"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1079\/BJN20041142","article-title":"Peripheral and central signals in the control of eating in normal, obese and binge-eating human subjects","volume":"92","author":"Geliebter","year":"2004","journal-title":"Br. J. Nutr."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","article-title":"Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study","volume":"381","author":"Buse","year":"2013","journal-title":"Lancet"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/2040622315620180","article-title":"The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity","volume":"7","author":"Crane","year":"2016","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"782","DOI":"10.4158\/EP.14.6.782","article-title":"Inhibition of renal glucose reabsorption: A novel strategy for achieving glucose control in type 2 diabetes mellitus","volume":"14","author":"DeFronzo","year":"2008","journal-title":"Endocr. Pract."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/dom.12064","article-title":"Inhibition of the sodium glucose co-transporter-2: Its beneficial action and potential combination therapy for type 2 diabetes mellitus","volume":"15","author":"Chen","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1159\/000526441","article-title":"From Antiquity to Modern Times: A History of Diabetes Mellitus and Its Treatments","volume":"95","author":"March","year":"2022","journal-title":"Horm. Res. Paediatr."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3810\/pgm.2013.09.2698","article-title":"Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus","volume":"125","author":"Barnett","year":"2013","journal-title":"Postgrad. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.metabol.2009.04.014","article-title":"Expression changes of angiotensin II pathways and bioactive mediators during human preadipocytes-visceral differentiation","volume":"58","author":"Ye","year":"2009","journal-title":"Metabolism"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12933-017-0511-0","article-title":"Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: A post hoc analysis","volume":"16","author":"Pfeifer","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11606-021-07227-0","article-title":"Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-analysis","volume":"37","author":"Alexander","year":"2022","journal-title":"J. Gen. Intern. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/dom.13620","article-title":"The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis","volume":"21","author":"Wang","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jjcc.2023.10.009","article-title":"Heart failure management guidelines: New recommendations and implementation","volume":"83","author":"Heidenreich","year":"2024","journal-title":"J. Cardiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s12020-017-1264-y","article-title":"Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology","volume":"56","author":"Klonoff","year":"2017","journal-title":"Endocrine"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1055\/s-0028-1119378","article-title":"Cardiovascular effects of disturbed insulin metabolism in metabolic syndrome and type 2 diabetes patients","volume":"41","author":"Forst","year":"2009","journal-title":"Horm. Metab. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S2213-8587(13)70006-8","article-title":"Short-term intensive insulin therapy in type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"1","author":"Kramer","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.2337\/diacare.27.11.2597","article-title":"Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function","volume":"27","author":"Li","year":"2004","journal-title":"Diabetes Care"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_94","first-page":"583","article-title":"The guidelines for the diagnosis prevention and treatment of type 2 diabetes mellitus\u20132005","volume":"145","author":"Tsur","year":"2006","journal-title":"Harefuah"},{"key":"ref_95","unstructured":"International Diabetes Federation (2025, May 01). Diabetes Atlas 2023. Available online: https:\/\/diabetesatlas.org\/."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/03009730903366075","article-title":"Pulsatility of insulin release\u2014A clinically important phenomenon","volume":"114","author":"Hellman","year":"2009","journal-title":"Upsala J. Med. Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.2337\/db12-0664","article-title":"Loss of pulsatile insulin secretion: A factor in the pathogenesis of type 2 diabetes?","volume":"61","author":"Wahren","year":"2012","journal-title":"Diabetes"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1053\/meta.2000.17700","article-title":"Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy","volume":"49","author":"Dailey","year":"2000","journal-title":"Metabolism"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.metabol.2010.01.004","article-title":"Pulsatile intermittent intravenous insulin therapy for attenuation of retinopathy and nephropathy in type 1 diabetes mellitus","volume":"59","author":"Weinrauch","year":"2010","journal-title":"Metabolism"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.metabol.2007.05.016","article-title":"A pilot study to test the effect of pulsatile insulin infusion on cardiovascular mechanisms that might contribute to attenuation of renal compromise in type 1 diabetes mellitus patients with proteinuria","volume":"56","author":"Weinrauch","year":"2007","journal-title":"Metabolism"},{"key":"ref_101","first-page":"49","article-title":"Pulsatile Insulin Infusion as a Treatment Option for Patients with Type 2 Diabetes and Stage III Kidney Failure\u2014Results from a Pilot Study","volume":"6","author":"Manessis","year":"2021","journal-title":"EC Endocrinol. Metab. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nut.2014.06.011","article-title":"Dietary carbohydrate restriction as the first approach in diabetes management","volume":"31","author":"Feinman","year":"2015","journal-title":"Nutrition"},{"key":"ref_103","first-page":"636","article-title":"Twelve-month outcomes of a randomized trial of a moderate-carbohydrate versus very low-carbohydrate diet in overweight adults with type 2 diabetes","volume":"147","author":"Saslow","year":"2017","journal-title":"J. Nutr."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3945\/ajcn.115.112581","article-title":"Comparison of low- and high-carbohydrate diets for type 2 diabetes management: A randomized trial","volume":"102","author":"Tay","year":"2015","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.diabres.2017.07.006","article-title":"Efficacy of low carbohydrate diet for type 2 diabetes mellitus management: A systematic review and meta-analysis of randomized controlled trials","volume":"131","author":"Meng","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s13300-018-0373-9","article-title":"Effectiveness and safety of a novel care model for the management of type 2 diabetes at one year: An open-label, non-randomized, controlled study","volume":"9","author":"Hallberg","year":"2018","journal-title":"Diabetes Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2337\/dc16-1728","article-title":"Physical Activity\/Exercise and Diabetes: A Position Statement of the American Diabetes Association","volume":"39","author":"Colberg","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_108","first-page":"1467","article-title":"The impact of resistance exercise training on glycemic control among adults with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Wan","year":"2024","journal-title":"J. Diabetes Sci. Technol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","article-title":"Novel subgroups of adult-onset diabetes and their association with outcomes: A data-driven cluster analysis of six variables","volume":"6","author":"Ahlqvist","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2337\/dci20-0022","article-title":"Precision Medicine in Diabetes: A Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"43","author":"Chung","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s43856-023-00360-3","article-title":"Precision subclassification of type 2 diabetes: A systematic review","volume":"3","author":"Misra","year":"2023","journal-title":"Commun. Med."},{"key":"ref_112","first-page":"1","article-title":"Successful Personalized Type 2 Diabetes Management for Airline Pilots by Means of \u00df-Cell-protective De-Escalation Treatment (DET)\u2014Background and Case Reports","volume":"4","author":"Jantz","year":"2025","journal-title":"Arch. Clin. Case Stud."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/4\/229\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T04:13:44Z","timestamp":1777090424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/4\/229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":112,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jpm16040229"],"URL":"https:\/\/doi.org\/10.3390\/jpm16040229","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]}}}